Phase i study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors

Yasuhito Fujisaka, Takayasu Kurata, Kaoru Tanaka, Toshihiro Kudo, Kunio Okamoto, Junji Tsurutani, Hiroyasu Kaneda, Isamu Okamoto, Masayuki Namiki, Chifumi Kitamura, Kazuhiko Nakagawa

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Amatuximab is a chimeric monoclonal antibody that targets mesothelin, which is expressed in virtually all mesotheliomas and pancreatic adenocarcinomas. The objective of this study was to determine the dose-limiting toxicity and the maximum tolerated dose. Patients with mesothelioma, pancreatic adenocarcinoma or other mesothelin-positive solid tumors were eligible for this study. Amatuximab was administered weekly as an intravenous infusion in 4-week cycles at progressively increasing doses ranging from 50 to 200 mg/m2. Seventeen patients received amatuximab. Two dose-limiting toxicities were observed: one at 50 mg/m2 and one at 200 mg/m2; the maximum tolerated dose of this study was determined to be 200 mg/m2. Of the 17 patients, 13 patients (76.5 %) experienced treatment-related adverse events. The most common adverse events were grade 1 fatigue (29.4 %) and pyrexia (23.5 %). The maximum serum concentration and area under the concentration curve values increased in an almost dose-proportional manner. Three patients had stable disease. Amatuximab was generally well tolerated at doses up to 200 mg/m2. The pharmacokinetic profile of amatuximab in the Japanese population was similar to that seen in the United States population (Clinical Trials.gov Identifier: NCT01018784).

Original languageEnglish
Pages (from-to)380-388
Number of pages9
JournalInvestigational New Drugs
Volume33
Issue number2
DOIs
Publication statusPublished - Apr 1 2015

Fingerprint

Monoclonal Antibodies
Maximum Tolerated Dose
Mesothelioma
Neoplasms
Adenocarcinoma
Intravenous Infusions
Population
Area Under Curve
Fatigue
Fever
Pharmacokinetics
mesothelin
MORAb-009 monoclonal antibody
Clinical Trials
Serum
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Phase i study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors. / Fujisaka, Yasuhito; Kurata, Takayasu; Tanaka, Kaoru; Kudo, Toshihiro; Okamoto, Kunio; Tsurutani, Junji; Kaneda, Hiroyasu; Okamoto, Isamu; Namiki, Masayuki; Kitamura, Chifumi; Nakagawa, Kazuhiko.

In: Investigational New Drugs, Vol. 33, No. 2, 01.04.2015, p. 380-388.

Research output: Contribution to journalArticle

Fujisaka, Y, Kurata, T, Tanaka, K, Kudo, T, Okamoto, K, Tsurutani, J, Kaneda, H, Okamoto, I, Namiki, M, Kitamura, C & Nakagawa, K 2015, 'Phase i study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors', Investigational New Drugs, vol. 33, no. 2, pp. 380-388. https://doi.org/10.1007/s10637-014-0196-0
Fujisaka, Yasuhito ; Kurata, Takayasu ; Tanaka, Kaoru ; Kudo, Toshihiro ; Okamoto, Kunio ; Tsurutani, Junji ; Kaneda, Hiroyasu ; Okamoto, Isamu ; Namiki, Masayuki ; Kitamura, Chifumi ; Nakagawa, Kazuhiko. / Phase i study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors. In: Investigational New Drugs. 2015 ; Vol. 33, No. 2. pp. 380-388.
@article{7fea496a34a44fb695841a2745cafd02,
title = "Phase i study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors",
abstract = "Amatuximab is a chimeric monoclonal antibody that targets mesothelin, which is expressed in virtually all mesotheliomas and pancreatic adenocarcinomas. The objective of this study was to determine the dose-limiting toxicity and the maximum tolerated dose. Patients with mesothelioma, pancreatic adenocarcinoma or other mesothelin-positive solid tumors were eligible for this study. Amatuximab was administered weekly as an intravenous infusion in 4-week cycles at progressively increasing doses ranging from 50 to 200 mg/m2. Seventeen patients received amatuximab. Two dose-limiting toxicities were observed: one at 50 mg/m2 and one at 200 mg/m2; the maximum tolerated dose of this study was determined to be 200 mg/m2. Of the 17 patients, 13 patients (76.5 {\%}) experienced treatment-related adverse events. The most common adverse events were grade 1 fatigue (29.4 {\%}) and pyrexia (23.5 {\%}). The maximum serum concentration and area under the concentration curve values increased in an almost dose-proportional manner. Three patients had stable disease. Amatuximab was generally well tolerated at doses up to 200 mg/m2. The pharmacokinetic profile of amatuximab in the Japanese population was similar to that seen in the United States population (Clinical Trials.gov Identifier: NCT01018784).",
author = "Yasuhito Fujisaka and Takayasu Kurata and Kaoru Tanaka and Toshihiro Kudo and Kunio Okamoto and Junji Tsurutani and Hiroyasu Kaneda and Isamu Okamoto and Masayuki Namiki and Chifumi Kitamura and Kazuhiko Nakagawa",
year = "2015",
month = "4",
day = "1",
doi = "10.1007/s10637-014-0196-0",
language = "English",
volume = "33",
pages = "380--388",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Phase i study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors

AU - Fujisaka, Yasuhito

AU - Kurata, Takayasu

AU - Tanaka, Kaoru

AU - Kudo, Toshihiro

AU - Okamoto, Kunio

AU - Tsurutani, Junji

AU - Kaneda, Hiroyasu

AU - Okamoto, Isamu

AU - Namiki, Masayuki

AU - Kitamura, Chifumi

AU - Nakagawa, Kazuhiko

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Amatuximab is a chimeric monoclonal antibody that targets mesothelin, which is expressed in virtually all mesotheliomas and pancreatic adenocarcinomas. The objective of this study was to determine the dose-limiting toxicity and the maximum tolerated dose. Patients with mesothelioma, pancreatic adenocarcinoma or other mesothelin-positive solid tumors were eligible for this study. Amatuximab was administered weekly as an intravenous infusion in 4-week cycles at progressively increasing doses ranging from 50 to 200 mg/m2. Seventeen patients received amatuximab. Two dose-limiting toxicities were observed: one at 50 mg/m2 and one at 200 mg/m2; the maximum tolerated dose of this study was determined to be 200 mg/m2. Of the 17 patients, 13 patients (76.5 %) experienced treatment-related adverse events. The most common adverse events were grade 1 fatigue (29.4 %) and pyrexia (23.5 %). The maximum serum concentration and area under the concentration curve values increased in an almost dose-proportional manner. Three patients had stable disease. Amatuximab was generally well tolerated at doses up to 200 mg/m2. The pharmacokinetic profile of amatuximab in the Japanese population was similar to that seen in the United States population (Clinical Trials.gov Identifier: NCT01018784).

AB - Amatuximab is a chimeric monoclonal antibody that targets mesothelin, which is expressed in virtually all mesotheliomas and pancreatic adenocarcinomas. The objective of this study was to determine the dose-limiting toxicity and the maximum tolerated dose. Patients with mesothelioma, pancreatic adenocarcinoma or other mesothelin-positive solid tumors were eligible for this study. Amatuximab was administered weekly as an intravenous infusion in 4-week cycles at progressively increasing doses ranging from 50 to 200 mg/m2. Seventeen patients received amatuximab. Two dose-limiting toxicities were observed: one at 50 mg/m2 and one at 200 mg/m2; the maximum tolerated dose of this study was determined to be 200 mg/m2. Of the 17 patients, 13 patients (76.5 %) experienced treatment-related adverse events. The most common adverse events were grade 1 fatigue (29.4 %) and pyrexia (23.5 %). The maximum serum concentration and area under the concentration curve values increased in an almost dose-proportional manner. Three patients had stable disease. Amatuximab was generally well tolerated at doses up to 200 mg/m2. The pharmacokinetic profile of amatuximab in the Japanese population was similar to that seen in the United States population (Clinical Trials.gov Identifier: NCT01018784).

UR - http://www.scopus.com/inward/record.url?scp=84939981252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939981252&partnerID=8YFLogxK

U2 - 10.1007/s10637-014-0196-0

DO - 10.1007/s10637-014-0196-0

M3 - Article

VL - 33

SP - 380

EP - 388

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -